Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Mar;56(3):1655-7.
doi: 10.1128/AAC.05452-11. Epub 2011 Dec 27.

Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen

Stéphanie Trancart  1 , Isabelle Charreau, Bruno Marchou, Muriel Bocquentin, Jean-Michel Molina, Jacques Izopet, Philippe Tangre, Jean-Pierre Aboulker, Anne-Marie Taburet; ANRS 106 Study Group
Collaborators, Affiliations
Clinical Trial

Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen

Stéphanie Trancart et al. Antimicrob Agents Chemother. 2012 Mar.

Abstract

Efavirenz concentrations were measured in 21 patients during an interruption cycle of the ANRS 106 Window trial. The median efavirenz concentrations in the patients 12 h, 3 days, and 7 days after discontinuation of the drug were 1,962 ng/ml, 416 ng/ml, and 112 ng/ml, respectively. The half-life ranged from 27 to 136 h. No relationship between efavirenz exposure and detection of nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations was demonstrated. Patients who were treated by a lamivudine- or emtricitabine-based regimen had a lower risk of NNRTI mutation selection.

PubMed Disclaimer

References

    1. Bazzoli C, et al. 2011. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob. Agents Chemother. 55:3423–3431 - PMC - PubMed
    1. Chaix ML, et al. 2006. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus Abidjan, Cote d'Ivoire. J. Infect. Dis. 193:482–487 - PubMed
    1. Chi BH, et al. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698–1705 - PubMed
    1. di Iulio J, et al. 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19:300–309 - PubMed
    1. Haas DW, et al. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400 - PubMed

Publication types

MeSH terms